<DOC>
	<DOCNO>NCT02140606</DOCNO>
	<brief_summary>To investigate safety , tolerability cafusertib combination low dose cytarabine ( LD-Ara-C ) Chinese patient relapsed/refractory AML eligible conventional intensive treatment . The dose cafusertib escalate determine dose limit toxicity ( DLT ) maximum tolerate dose ( MTD ) cafusertib combination LD-Ara-C AML patient . At time , pharmacokinetic characteristic preliminary efficacy cafusertib observe AML patient . To determine recommended dosage regimen phase II .</brief_summary>
	<brief_title>Phase I Trial Investigate Cafusertib Hydrochloride Combination With Low Dose Cytarabine Chinese Patients With Acute Myeloid Leukaemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Signed write informed consent consistent Chinese Good Clinical Practice . Male female patient age &gt; /= 18 year time inform consent . Patients relapsed/refractory AML ineligible conventional intensive treatment . Eastern Cooperative Oncology Group performance status score 0 2 screening . Life expectancy least 3 month . Adequate hepatic , renal metabolic function parameter : Serum total bilirubin ≤1.5 x upper limit normal , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) ≤2.5 x upper limit normal ; Creatinine clearance rate ≥60ml/min , Serum creatinine ≤1.0 x upper limit normal ; Relatively normal ECG ( electrocardiogram ) , QTc &lt; 450 m ( male ) , QTc &lt; 470 m ( female ) ; LVEF &gt; 50 % . Patients comply trial followup procedure . Patients receive cafusertib hydrochloride PLK inhibitor . Patients APL . Patients central nervous system leukemia . Need continue use cytokine therapy screening . Patients participate clinical trial within 4 week prior enrollment . Patient severe infection . Patients myocardial infarction occur within six month prior enrollment . Severe heart disease , include NYHA class II cardiac dysfunction . Patients HIV infection acute chronic viral hepatitis . Severe gastrointestinal disorder ( bleed , infection , obstruction great grade 1 diarrhea ) . A previous history neurological psychiatric disorder , include epilepsy dementia . Concomitant medication CYP3A4 inhibitor , inducer substrate ; Women pregnant breast feeding . Subject think unfit study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>AML</keyword>
	<keyword>phase1</keyword>
	<keyword>MTD</keyword>
	<keyword>Cafusertib</keyword>
</DOC>